Nivolumab Phase 3 Trial for Advanced Pleural Mesothelioma Completes Primary…

The Phase 3 clinical trial (NCT04334759) investigating nivolumab in combination with chemotherapy for advanced pleural mesothelioma has reached its primary completion date on June 20, 2025. This milestone indicates that the main data collection for the study's primary endpoint has concluded.

Background

Pleural mesothelioma is a rare and aggressive cancer that originates in the lining of the lungs. The trial, titled "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma," explores treatment options for patients whose pleural mesothelioma cannot be surgically removed. Nivolumab is an immunotherapy, a type of treatment that helps the body's immune system fight cancer.

Trial design

The study, identified as NCT04334759, is a Phase 3, randomized clinical trial that enrolled 214 participants. It focuses on patients with pleural mesothelioma, specifically those with advanced or malignant pleural mesothelioma. Participants were assigned to receive either standard chemotherapy (cisplatin or carboplatin and pemetrexed) in combination with durvalumab, or a treatment chosen by the study doctor. The comparator arm included standard chemotherapy or an immunotherapy combination of ipilimumab and nivolumab. The primary outcomes for this study were not detailed in the provided data.

What this means

The primary completion of this Phase 3 trial signifies that all participants have completed the treatment and follow-up necessary to assess the primary outcome. While specific results are not yet available, this step is crucial for the eventual analysis and reporting of the trial's findings, which will inform potential future treatment strategies for advanced pleural mesothelioma.

Source

Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The event for study NCT04334759, titled "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma," was recorded as a primary completion on June 20, 2025, on clinicaltrials.gov.